Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

fulgent genetics inc - FLGT

FLGT

Close Chg Chg %
27.16 -0.15 -0.55%

Pre-Market

27.01

-0.15 (0.55%)

Volume: 121.81K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Trade Now

Company Overview: fulgent genetics inc - FLGT

FLGT Key Data

Open

$27.14

 Day Range

26.75 - 27.14

52 Week Range

14.57 - 31.04

 Market Cap

$839.58M

Shares Outstanding

30.91M

 Public Float

19.98M

Beta

0.65

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.40

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

216.06K

  

FLGT Performance

1 Week
 
 -2.17%
 
1 Month
 
 -8.69%
 
3 Months
 
 19.57%
 
1 Year
 
 47.03%
 
5 Years
 
 -40.99%
 

FLGT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About fulgent genetics inc - FLGT

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

FLGT At a Glance

Fulgent Genetics, Inc.
4399 Santa Anita Avenue
El Monte, California 91731
Phone 1-626-350-0537 Revenue 283.47M
Industry Medical/Nursing Services Net Income -42,708,000.00
Sector Health Services Employees 1,313
Fiscal Year-end 12 / 2025
View SEC Filings

FLGT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.97
Price to Book Ratio 0.503
Price to Cash Flow Ratio 26.52
Enterprise Value to EBITDA -6.236
Enterprise Value to Sales 1.078
Total Debt to Enterprise Value 0.03

FLGT Efficiency

Revenue/Employee 215,894.897
Income Per Employee -32,527.037
Receivables Turnover 3.68
Total Asset Turnover 0.224

FLGT Liquidity

Current Ratio 4.85
Quick Ratio 4.85
Cash Ratio 3.541

FLGT Profitability

Gross Margin 35.013
Operating Margin -26.076
Pretax Margin -18.329
Net Margin -15.066
Return on Assets -3.376
Return on Equity -3.764
Return on Total Capital -3.738
Return on Invested Capital -3.737

FLGT Capital Structure

Total Debt to Total Equity 0.814
Total Debt to Total Capital 0.808
Total Debt to Total Assets 0.734
Long-Term Debt to Equity 0.615
Long-Term Debt to Total Capital 0.61
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fulgent Genetics Inc - FLGT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
992.58M 618.97M 289.21M 283.47M
Sales Growth
+135.37% -37.64% -53.27% -1.99%
Cost of Goods Sold (COGS) incl D&A
217.24M 258.56M 192.60M 184.22M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
12.16M 36.91M 31.76M 24.93M
Depreciation
10.45M 30.41M 23.91M 16.96M
Amortization of Intangibles
1.71M 6.50M 7.84M 7.96M
COGS Growth
+141.90% +19.02% -25.51% -4.35%
Gross Income
775.34M 360.40M 96.61M 99.25M
Gross Income Growth
+133.60% -53.52% -73.19% +2.73%
Gross Profit Margin
+78.11% +58.23% +33.40% +35.01%
2021 2022 2023 2024 5-year trend
SG&A Expense
96.59M 178.90M 171.91M 173.17M
Research & Development
24.22M 28.91M 41.44M 48.82M
Other SG&A
72.37M 149.99M 130.47M 124.35M
SGA Growth
+131.37% +85.22% -3.91% +0.73%
Other Operating Expense
- - - -
-
Unusual Expense
2.80M 2.98M 120.23M 10.07M
EBIT after Unusual Expense
675.95M 178.53M (195.53M) (83.99M)
Non Operating Income/Expense
1.35M 6.15M 58.44M 32.03M
Non-Operating Interest Income
1.30M 5.30M 21.10M 31.47M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 650.00K 37.00M
-
Interest Expense Growth
- - - +5,592.31%
-
Gross Interest Expense
- - 650.00K 37.00M
-
Interest Capitalized
- - - -
-
Pretax Income
677.30M 184.03M (174.09M) (51.96M)
Pretax Income Growth
+132.20% -72.83% -194.60% +70.15%
Pretax Margin
+68.24% +29.73% -60.19% -18.33%
Income Tax
174.79M 42.10M 1.15M (8.14M)
Income Tax - Current - Domestic
182.98M 50.38M (10.31M) (4.55M)
Income Tax - Current - Foreign
- - - 148.00K
-
Income Tax - Deferred - Domestic
(8.19M) (8.28M) (8.67M) (11.05M)
Income Tax - Deferred - Foreign
- - 20.14M 7.31M
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
502.50M 141.92M (175.24M) (43.82M)
Minority Interest Expense
(1.13M) (1.48M) (7.41M) (1.11M)
Net Income
503.63M 143.40M (167.82M) (42.71M)
Net Income Growth
+130.32% -71.53% -217.03% +74.55%
Net Margin Growth
+50.74% +23.17% -58.03% -15.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
503.63M 143.40M (167.82M) (42.71M)
Preferred Dividends
- - - -
-
Net Income Available to Common
503.63M 143.40M (167.82M) (42.71M)
EPS (Basic)
17.1256 4.7647 -5.6347 -1.4125
EPS (Basic) Growth
+77.74% -72.18% -218.26% +74.93%
Basic Shares Outstanding
29.41M 30.10M 29.78M 30.23M
EPS (Diluted)
16.2587 4.6313 -5.6347 -1.4125
EPS (Diluted) Growth
+78.87% -71.51% -221.67% +74.93%
Diluted Shares Outstanding
30.98M 30.96M 29.78M 30.23M
EBITDA
690.91M 218.41M (43.54M) (48.99M)
EBITDA Growth
+135.38% -68.39% -119.93% -12.52%
EBITDA Margin
+69.61% +35.29% -15.05% -17.28%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 30.00
Number of Ratings 3 Current Quarters Estimate 0.03
FY Report Date 12 / 2025 Current Year's Estimate 0.28
Last Quarter’s Earnings 0.14 Median PE on CY Estimate N/A
Year Ago Earnings 0.49 Next Fiscal Year Estimate -0.32
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate 0.03 -0.11 0.28 -0.32
High Estimates 0.07 -0.02 0.32 -0.07
Low Estimate -0.03 -0.19 0.22 -0.60
Coefficient of Variance 177.06 -73.79 18.89 -83.15

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Fulgent Genetics Inc - FLGT

Date Name Shares Transaction Value
May 20, 2025 Michael Nohaile Director 19,020 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Michael Nohaile Director 6,311 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Regina E. Groves Director 16,982 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Linda Marsh Director 27,641 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Paul H. Kim CFO and Treasurer 348,282 Open market or private purchase of non-derivative security Non-derivative transaction at $15.96 per share 5,558,580.72
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 766,212 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Han Lin Gao Chief Scientific Officer 921,017 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 817,078 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.24 per share 13,269,346.72
Feb 28, 2025 Jian Xie President and COO 380,338 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.24 per share 6,176,689.12
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 730,631 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 11,901,978.99
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 750,628 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 12,227,730.12
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 760,171 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 12,383,185.59
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 729,015 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Ming Hsieh Chief Executive Officer; Director 711,195 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Paul H. Kim CFO and Treasurer 249,838 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.24 per share 4,057,369.12
Feb 28, 2025 Paul H. Kim CFO and Treasurer 254,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Paul H. Kim CFO and Treasurer 210,301 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 3,425,803.29
Feb 28, 2025 Paul H. Kim CFO and Treasurer 218,529 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 3,559,837.41
Feb 28, 2025 Paul H. Kim CFO and Treasurer 221,553 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.29 per share 3,609,098.37
Feb 28, 2025 Paul H. Kim CFO and Treasurer 223,467 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Fulgent Genetics Inc in the News